MedTrace Logo

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

NCT07185269 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2025-11-26

No results posted yet for this study

Summary

This study will evaluate the effect and safety of 626 in patients with SLE

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

626

626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.

DRUG

626

626 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2028-08-12
Completion
2028-11-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185269 on ClinicalTrials.gov